Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group

M. Cicardi, W. Aberer, A. Banerji, M. Bas, J. A. Bernstein, K. Bork, T. Caballero, H. Farkas, A. Grumach, A. P. Kaplan, M. A. Riedl, M. Triggiani, A. Zanichelli & B. Zuraw on behalf of HAWK, under the patronage of EAACI (European Academy of Allergy and Clinical Immunology)

Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Luigi Sacco Hospital Milan, Milan, Italy; Department of Dermatology, Medical University of Graz, Graz, Austria; Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA; Department of Otorhinolaryngology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Division of Immunology/Allergy Section, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Department of Dermatology, Johannes Gutenberg University, Mainz, Germany; Department of Allergy, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare Diseases–U754 (CIBERER), Madrid, Spain; 3rd Department of Internal Medicine, National Angioedema Center, Semmelweis University, Budapest, Hungary; Department of Clinical Medicine, Faculty of Medicine ABC, Sao Paulo, Brazil; Medical University of South Carolina, Charleston, SC; Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California – San Diego, La Jolla, CA, USA; Department of Medicine, University of Salerno, Salerno, Italy

To cite this article: Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T, Farkas H, Grumach A, Kaplan AP, Riedl MA, Triggiani M, Zanichelli A, Zuraw B on behalf of HAWK, under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; DOI: 10.1111/all.12380.

Keywords
angioedema; clinical immunology; dermatology; education; urticaria.

Abstract
Angioedema is defined as localized and self-limiting edema of the subcutaneous and submucosal tissue, due to a temporary increase in vascular permeability caused by the release of vasoactive mediator(s). When angioedema recurs without significant wheals, the patient should be diagnosed to have angioedema as a distinct disease. In the absence of accepted classification, different types of angioedema are not uniquely identified. For this reason, the European Academy of Allergy and Clinical Immunology gave its patronage to a consensus conference aimed at classifying angioedema. Four types of acquired and three types of hereditary angioedema were identified as separate forms from the analysis of the literature and were presented in detail at the meeting. Here, we summarize the analysis of the data and the resulting classification of angioedema.

Angioedema is defined as localized and self-limiting edema of the subcutaneous and submucosal tissue, due to a temporary increase in vascular permeability caused by the release of vasoactive mediator(s). It frequently occurs as part of urticaria, which is characterized by two symptoms: wheals, edema of superficial skin layers, and angioedema, edema of deep skin layers (1). When angioedema recurs without significant wheals, the patient should be diagnosed to have angioedema as a distinct disease. Quincke, in his paper on ‘circumscribed edema’ that he called ‘angioneurotic edema’ (2), was the first author who considered angioedema to be a separate entity. Because of that, angioedema is still frequently referred to as Quincke edema. Shortly thereafter, Osler (3), in his seminal paper ‘Hereditary angioneurotic edema’, gave the first exhaustive description of an angioedema standing as a specific nosology entity, which was later renamed hereditary angioedema (HAE). In 1963, Donaldson and Evans identified C1 inhibitor (C1-INH) deficiency as the...
genetic defect underlying the disease described by Osler (4). Nine years later, Caldwell et al. (5) identified an angioedema patient in whom the deficiency of C1-INH was not hereditary, but acquired, related to a concomitant lymphosarcoma. In subsequent years, angioedema research has been focused at unraveling the pathophysiology of angioedema related to C1-INH deficiency, eventually shown to be bradykinin-mediated, a conclusion proven correct by the clinical response to a specific antagonist (6). The advent in 1980 of angiotensin-converting enzyme inhibitors (ACEI), which encompass angioedema as a side-effect, changed the fate of this disease. Even if this side-effect occurs in <1% of treated subjects, the millions of people receiving an ACEI worldwide increased the incidence of angioedema (7) and angioedema became the second most common cause of hospitalization for allergic diseases after asthma (8). In 2000, Bork et al. (9) described a form of HAE without C1-INH deficiency further widening the spectrum of angioedema types.

Thus, diagnosis of angioedema needs to be refined by the specification of the type. In the absence of an accepted classification, different types of angioedema are not uniquely identified. For this reason, the European Academy of Allergy and Clinical Immunology (EAACI) gave its patronage to a consensus conference aimed at classifying angioedema. This conference was held from September 30, 2012 to October 2, 2012 in Gargnano del Garda, Italy. Attendance was based on the HAWK group of angioedema experts, established in 2010 to provide evidence-based recommendations for the treatment for HAE (10). Four types of acquired and three types of HAE were identified as separate forms from the analysis of the literature and were presented in detail at the meeting. Here, we summarize the analysis of the data and the resulting classification of angioedema (Fig. 1).

**Idiopathic histaminergic acquired angioedema (IH-AAE)**

Continuous administration of an antihistamine stops disease recurrences in a significant proportion of non-HAE patients, and this angioedema can be defined as ‘histaminergic’. The term implies a role for the cutaneous mast cell and/or the blood basophil and suggests that bradykinin or other vasoactive substances will not be predominantly released. Histamine release suggests the possibility of an allergic cause and identifying such causes is the starting point in the evaluation of patients with angioedema. Allergy is suspected if the recurrence of symptoms is sequential related to an exogenous stimulus and confirmed by a positive skin prick test and/or detection of clinical significant specific IgE. Stimuli such as...
medication and/or foods, insect bites/stings or other environmental allergens, or physical stimuli may be detected by an experienced allergist: they are frequently involved in patients with acute angioedema, but only in a minority with recurrent attacks. Furthermore, an unequivocal causal relationship between infection or autoimmune disease and angioedema is frequently difficult to confirm. When allergy and other causes have been ruled out and an etiology cannot be identified, the histaminergic angioedema is defined to be idiopathic or spontaneous. A series of 929 consecutive patients with angioedema without urticaria presenting over a 10-year period at a large angioedema specialty center (11) identified 124 patients (16%) where a specific factor could be identified (a food, drug, insect bite, environmental allergen, or other physical stimulus), 55 (7%) with autoimmune disease or infection, 85 (11%) being ACE inhibitor related, 197 (25%) suffering from HAE, and 294 cases of idiopathic angioedema. Among the latter 294 patients with unknown etiology, the vast majority (254 or 87%) responded well to long-term antihistamines and were thus classified as being idiopathic histaminergic.

In idiopathic angioedema that is histaminergic, patients by definition respond to high-dose antihistamines used prophylactically on a daily basis (12). However, the mechanism by which histamine release is initiated in this disorder is unknown.

**Clinical presentation**

Due to the lack of publications addressing the problem of clinical presentation of this form of angioedema, the following data have been derived by the discussion among experts. IH-AAE develops rapidly reaching a maximum within 6 h; precipitating factors are not identified; drug history is irrelevant to the angioedema; the face is mostly affected; gastrointestinal and laryngeal mucosa are spared and death due to the angioedema has not been reported; there is no preferred age for onset; attacks are prevented by antihistamine and respond to corticosteroids and epinephrine as acute treatment; family history for angioedema is negative; there are no associated diseases.

**Diagnosis**

Major diagnostic tools include exclusion of causes of angioedema when potentially present based on the clinical features: causative agents associated autoimmune/infectious disease, C1-INH deficiency, and mutation in factor XII. In the absence of an algorithm specific for angioedema, we suggest employing the guidelines for diagnosis of urticaria (1). If anaphylaxis is suspected, measurement of serum mast cell tryptase; skin prick testing or specific IgE antibodies, can be indicated; rheumatoid factor, antinuclear antibodies, C3/C4 complement levels, and C1q antibodies if connective tissue disease or urticarial vasculitis is suspected. Screening for infectious foci when no obvious cause of angioedema is detectable is rarely helpful. In the only published study of angioedema without urticaria (11), appropriate treatment for a concomitant infection markedly improved the angioedema in all patients with dental granuloma: three of five patients with sinusitis and five of seven patients with urinary tract infection. In two patients infected with *Helicobacter pylori* who experienced gastroesophageal reflux, angioedema improved after proper eradication therapy in one case only.

In conclusion, IH-AAE seems to be the most common form of angioedema. Some of its clinical and pathogenetic features are similar to idiopathic recurrent urticaria. It is diagnosed on clinical features, exclusion findings, and therapeutic response. Antihistamine and corticosteroids represent the basic treatment.

**Idiopathic nonhistaminergic acquired angioedema**

This type of angioedema identifies nonfamilial, nonhereditary forms in which known causes of angioedema have been excluded as for IH-AAE, but recurrences persist upon antihistamine treatment. Search of the medical literature matching the terms idiopathic, nonhistaminergic, and angioedema provides just a few papers (11, 13–16). Nevertheless, experts placed an effort in providing a definition of this angioedema for the strong belief that it could encompass a distinct, homogeneous group of patients. Cicardi et al. (12) first used this term for describing a group of patients with angioedema: these patients presented with remarkable response to tranexamic acid given for prophylaxis. A similar favorable effect of tranexamic acid was reported in another series of angioedema patients with analogous characteristics, but defined as ‘sporadic idiopathic bradykinin angioedema’ (17). The term ‘bradykinin-mediated’ is sometimes substituted for ‘nonhistaminergic’ assuming that bradykinin mediates this angioedema. Even if experts agree that bradykinin is involved in InH-AAE, experimental evidence confirming this hypothesis is still limited. Cugno et al. (18) showed that one patient with InH-AAE had high levels of bradykinin in the venous blood effluent from the swollen arm, while in a similar situation, but with IH-AAE, bradykinin levels were normal. Additional evidence supportive of bradykinin as the mediator in this situation comes from scattered case reports showing efficacy of the bradykinin receptor antagonist icatibant in reverting angioedema that is not responsive to antihistamine (19–21). Until such findings are confirmed in a significant series of patients, we prefer to maintain the term nonhistaminergic for patients with angioedema not prevented by antihistamine. Furthermore, at least in some patients with angioedema not responsive to antihistamines, a role for vasoactive mediators other than bradykinin, for example cysteinyl leukotrienes, prostaglandins, or platelet-activating factor, should be considered.

**Clinical presentation**

Only two series of patients, 40 Italian and 35 French, can be found in the literature to be considered representative of InH-AAE (11, 17). Analysis of the Italian and French case lists shows a slightly higher frequency of male gender (1.35 and 1.5, respectively) and age of onset at 36 and 42 year old. Nearly all patients reported a facial location; abdominal
symptoms were present in <30% and upper airways' involvement in 35% and 26%. Invasive management (endotracheal intubation) for upper airway edema was reported for a single patient in the Italian group. The mean duration of symptoms was below 48 h and the frequency of recurrences high, with more than half of the patients needing continuous prophylaxis with tranexamic acid.

**Diagnosis**

The clinical history is the first step to diagnosis. In the absence of laboratory testing or biomarkers, the evidence supporting that histamine is not the putative mediator is based on the patient's negative response to continuous treatment with antihistamines. Based on recent recommendations for urticaria and angioedema (22), we can agree on the fact that second-generation antihistamines (azelastine, bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, mizolastine, and rupatadine) at licensed doses represent the first approach for these patients. Up to four times increase in doses can be employed prophylactically before concluding that InH-AAE is the diagnosis.

**Treatment**

There is no conclusive evidence for an effective treatment for attacks of idiopathic nonhistaminergic angioedema. Efficacy of tranexamic acid has been reported in two case series, but no detailed data are available (11, 17). Case reports indicate that icatibant can relieve symptoms of angioedema in these patients and in individuals over 65 years of age (32, 38). The latency between the initiation of ACEI therapy and the onset of symptoms can vary greatly from a few hours to several years, but it is more likely to occur early after initiation of ACEI therapy (34, 39–42).

Acquired angioedema related to angiotensin-converting enzyme inhibitors (ACEI-AAE) have been reported (43, 46, 47). The inhibition of ACE, which is involved in the breakdown of bradykinin to inactive peptides, results in elevated plasma levels of bradykinin that further increase during ACEI-AAE (24, 25). The suggestion that ACEI-AAE is bradykinin-mediated is reinforced by evidence that genomic and plasma variability of proteins interfering with bradykinin catabolism is associated with risk of ACEI-AAE (26–31).

**Incidence**

Analysis of large cohorts of hypertensive patients suggests angioedema to occur in <0.5% of patients taking ACEI, but 3–4.5-fold more often in black than in Caucasian subjects (32–36). A meta-analysis of clinical trials evaluating angioedema as a side-effect, reported an incidence of angioedema of 0.30% (95% CI 0.28–0.32) with ACEI, 0.11% (95% CI 0.09–0.13) with ARB, 0.13% (95% CI 0.08–0.19) with direct renin inhibitors, and 0.07% (95% CI 0.05–0.09) with placebo (37). Based on these data, there was an agreement among experts that an ARB-related angioedema should not be included as a specific form of angioedema.

**Clinical symptoms**

Acquired angioedema related to angiotensin-converting enzyme inhibitors is more frequent in female than male patients and in individuals over 65 years of age (32, 38). The switch to a different antihypertensive therapy, including an ARB, did not seem to influence although underdiagnoses of this complication cannot be excluded (44, 45). Deaths from laryngeal edema due to ACEI-AE have been reported (43, 46, 47).

**Diagnosis**

There is no test specifically modified during ACEI-AAE, and therefore, it is diagnosed upon onset of not otherwise explained angioedema in patients taking ACEI.

**Therapy of ACEI-AAE**

To prevent ACEI-AAE recurrences, the drug should be immediately discontinued. Surprisingly, ACEI withdrawal is not 100% effective. Long-term follow-up of 111 patients with ACE-AE demonstrated that after discontinuation from ACEI, 51 patients (46%) had further recurrences of angioedema with a frequency that was milder in 32 and remained unchanged in 18 (48). The switch to a different antihypertensive therapy, including an ARB, did not seem to influence the relapse. On the other hand, continued use of ACEI in spite of angioedema results in a marked increase in the incidence of recurrent angioedema with serious morbidity (39, 40). The reason for persistence of angioedema after ACEI withdrawal is not clear. It is possible to speculate that such
Pathophysiology suggests that bradykinin-targeted drugs, licensed to treat HAE due to C1 inhibitor deficiency, could be effective to reverse symptoms in ACEI-AAE (8, 49–52). Due to the lack of efficacy of corticosteroids and epinephrine, some of them have been used off label in ACEI-AAE. In an uncontrolled study, in 20 patients with ACEI-AAE, icatibant led to a rapid and complete disappearance of symptoms (mean 4.5 h) (53). A multicenter, double-blind study with icatibant in 30 patients with ACEI-AAE (Clin Trial Gov. No: NCT01154361) was completed, and the first data are expected in 2014. Potential effect of C1-INH is supported by published case reports (54–56). To verify these initial positive observations and the efficacy of kallikrein antagonist ecallantide, randomized studies are planned (ClinicalTrials.gov Identifier: NCT01843530 and NCT01036659).

When the course is fulminant despite drug therapy, or airway obstruction remains impending, securing of airways is indicated. Depending on the location of angioedema, different forms of airway securement may be selected (57).

**Acquired angioedema with C1 inhibitor deficiency**

The nongenetic nature of acquired angioedema with C1 inhibitor deficiency (C1-INH-AAE) implies that no mutations in C1-INH gene (SERPING1) and no family history of angioedema can be associated with this disease. In the absence of epidemiological studies, prevalence of C1-INH-AAE in the general population is estimated to be 1:10 that of the hereditary form, that is, around 1:500 000 (58).

**Pathophysiology and associated diseases**

Studies on plasma from patients with C1-INH-AAE indicate consumption of C1-INH and classical pathway complement components and, during attacks, activation of contact system with release of bradykinin, which causes angioedema (59–63). The lymphoproliferative disease, frequently found in these patients, could directly contribute to the consumption of C1 and C1-INH (5, 64–66). Evidence that curing the associated lymphoma could cure biochemical and clinical signs of angioedema confirms that lymphoma can be responsible for C1-INH-AAE (49, 67, 68).

Acquired angioedema with C1 inhibitor deficiency can be caused by autoantibodies neutralizing C1-INH function (50)-binding epitopes mapped around its reactive center (51, 52, 69–73). Although initially identified as an independent form of acquired C1-INH deficiency, large case series demonstrated that C1-INH-AAE with autoantibodies and with lymphoproliferative diseases largely overlaps and should be considered the same disease (49, 74, 75). Other conditions, mainly SLE, are reported in C1-INH-AAE, which appears as a syndrome with different possible associations (76). However, 20 of the 180 cases reported in the literature had no underlying disease associated with their C1-INH-AAE.

**Clinical presentation and diagnosis**

Acquired angioedema with C1 inhibitor deficiency starts after the age of 40 years in 94% of patients. Family history of angioedema is never present. Angioedema predominantly involves the face, tongue, uvula, and upper airways although any place in the body can swell (77, 78). Gastrointestinal swelling attacks are less common in C1-INH-AAE patients compared to C1-INH-HAE patients (77, 78).

Plasma levels of C1-INH function below 50% of normal are the confirmatory test when diagnosis of C1-INH-AAE is suspected. Antigen levels of C1-INH are similarly reduced. However, the presence of cleaved C1-INH may give apparently normal C1-INH antigen in about 20% of patients (76, 79). Significant reduction in C4 plasma levels is almost invariably present. In some patient, at disease onset, C1-INH deficiency and consumption of complement components can only be evident during angioedema attacks (80). The majority (70% or more) of C1-INH-AAE patients have a low Clq levels and anti-C1-INH antibodies (76). When clinical and biochemical data are not clear-cut to exclude hereditary C1-INH deficiency, genetic analysis to exclude SERPING1 mutations may be necessary to confirm C1-INH-AAE.

C1-INH-AAE patients should have routine clinical testing to rule out underlying lymphoproliferative and autoimmune diseases and MGUS. Testing should include a CBC with differential, sedimentation rate, C-reactive protein, serum protein electrophoresis, urine analysis for light chain proteins, and if there are peripheral blood abnormalities suggestive of a concomitant disease, then bone marrow biopsy should be performed to rule out malignancies (81).

**Treatment**

Treatment of C1-INH-AAE should consider the underlying disease as well as the frequency and severity of angioedema. Curing the underlying disease, when present, can cure angioedema, and this option should be considered. However, when the underlying disease does not per se require treatment (as for slow-growing lymphoproliferative diseases), taking into consideration the burden derived from angioedema symptoms versus the toxicity of treatment should always be considered in the decision-making process. Symptomatic treatment for angioedema recurrences can in fact be provided using bradykinin-targeted drugs. In the absence of controlled trials, these treatments are used off label in C1-INH-AAE.

Some case reports suggest the possibility to treat C1-INH-AAE with rituximab, a recombinant monoclonal antibody that targets CD20 surface antigens on B cells (49, 67, 82–85). Most of these cases had fewer and less severe attacks after treatment, and some actually went into remission and experienced no further attacks.

Treatment for angioedema symptoms in patients with C1-INH-AAE has been performed with C1-INH replacement therapy (86). The majority of patients respond positively, but some may be resistant to this treatment due to an extremely rapid catabolism of C1-INH (70). There are a few case...
Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE)

Hereditary angioedema with C1-INH deficiency (C1-INH-HAE) is a rare disease with minimal prevalence varying from 1.09/100 000 to 1.51/100 000 inhabitants (94–96) and an estimated prevalence of 1/10 000–1/100 000 inhabitants (97, 98).

Genetic defect and pathophysiology

C1-INH-HAE is due to mutations in one of the two alleles of C1-INH gene, SERPING1. A few homozygous mutations were described, mostly in patients with consanguineous parents (99–101). Structural abnormalities of the SERPING1 in patients with C1-INH-HAE are very heterogeneous (102–105), with prevalence of de novo mutations around 25% of cases (106, 107). The mutations described in C1-INH-HAE are collected in large universal genetic databases (OMIM ID 106100, Human Gene Mutation Database 119041) and in a database specific to this disease (http://hae.enzim.hu) (108).

Mutations in SERPING1 result in reduced plasma levels of C1-INH and instability of the contact system with facilitated release of bradykinin, identified as the key mediator of angioedema. Two phenotypic variants have been described (109). Type I is characterized by a quantitative decrease in C1-INH, which results in diminished functional activity (C1-INH-HAE type I), and type II is characterized by normal or high levels of C1-INH, which is dysfunctional.

Clinical presentation

C1-INH-HAE is clinically manifested by recurrent, localized subcutaneous or submucosal edema lasting for 2–5 days. The most commonly involved organs include the skin, upper respiratory airways, and gastrointestinal tract. The clinical expression is highly variable among the patients, from asymptomatic cases to patients suffering from disabling and life-threatening attacks with a demonstrated humanistic and economic burden (110, 111). Almost all patients with C1-INH-HAE present recurrences of abdominal pain caused by temporary bowel obstruction because of mucosal edema (98, 112). It is common that patients with C1-INH-HAE undergo unnecessary surgery misdiagnosing for surgical emergency a gastrointestinal angioedema.

Diagnosis

Suspected with above-mentioned symptoms, diagnosis of C1-INH-HAE needs laboratory confirmation (98). Patients with C1-INH-HAE present with low C4, and to a lesser extent low C2, because of consumption due to the activation of the classical complement pathway lacking its physiological inhibitor C1-INH. Measurement of C4 levels is used for screening of C1-INH-HAE because it is decreased even in between attacks and only exceptionally can be normal (113). Diagnosis is confirmed by the evidence of plasma C1-INH levels below 50% of the normal values (93). Based on the relative frequency of the two phenotypic variants of C1-INH-HAE, 15% of patients will have normal quantitative plasma levels of C1-INH. For this portion of patients, diagnosis requires measurement of C1-INH activity in plasma. Two methods (chromogenic or immunoenzymatic), based on measurement of the capacity of plasma to inhibit the esterase activity of a fix amount of C1s, are currently available to measure C1-INH activity. Neither is routinely performed in diagnostic laboratories (114). The chromogenic assay is usually preferred due to higher positive predictive value close to 100%. Blood samples for functional assay should be cautiously taken and handled to avoid in vitro loss of activity. Recently, an international collaborative study established the WHO 1st international standards for C1-inhibitor, plasma, and concentrate (115). It is suggested by experts that diagnosis of C1-INH-HAE should be based on two reduced readings of C4 and quantitative and/or functional C1-INH, separated by 1–3 months (116). Use of low C4 levels plus low C1-INH functional activity for the diagnosis of C1-INH deficiency has a specificity of 98–100% and a negative predictive value of 96% (117, 118). Patients with C1-INH-HAE usually do not consume C1 complex, and reduction in plasma levels of C1q is rare in nonhomozygous forms (99–101, 119, 120).

Genetic testing is needed during the first year of age, when C1-INH plasma levels may be falsely low and to distinguish C1-INH-AAE when diagnosis is not clear-cut (116). Heterogeneity of mutations responsible for C1-INH-HAE makes genetic diagnosis relatively complicated.

Treatment

Treatment of patients with C1-INH-HAE is aimed at avoiding mortality and reducing morbidity. As morbidity is function of frequency and severity of attacks and mortality of progression of laryngeal edema, effective treatments should prevent and/or revert angioedema symptoms. Several drugs, tested in double-blind placebo-controlled studies, retain such an efficacy and are available, with differences from country to country (Table 1) (6, 121–128). Several international consensus papers, released since 2004, guide the treatment of C1-INH-HAE, and here, we will provide just the general principles derived from these guidelines (10, 116, 129–132). After
<table>
<thead>
<tr>
<th>Drug</th>
<th>Trade name</th>
<th>Company</th>
<th>Drug description</th>
<th>Mechanism of action</th>
<th>Admin route</th>
<th>Indications and doses</th>
<th>Adverse events</th>
<th>Regulatory status</th>
<th>USA approvals</th>
<th>EU approvals</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1-INH</td>
<td>Berinert®</td>
<td>CSL Behring</td>
<td>Human plasma-derived C1-INH</td>
<td>Replacement of deficient protein</td>
<td>I.V.</td>
<td>Adults: 1000 IU 1-6 h before procedure</td>
<td>Rare: risk of anaphylaxis, thrombosis. Theoretical: transmission of infectious agent</td>
<td>Acute treatment, Self-admin</td>
<td>Acute treatment, STP</td>
<td>Self-admin</td>
</tr>
<tr>
<td>C1-INH</td>
<td>Csibor®, Grey®</td>
<td>Sanquin, Vinpharma</td>
<td>Human plasma-derived C1-INH</td>
<td>Replacement of deficient protein</td>
<td>I.V.</td>
<td>1000 IU if no response in 1 h</td>
<td>1000 IU 1-24 h preprocedure</td>
<td>LTP Self-admin</td>
<td>LTP Self-admin</td>
<td></td>
</tr>
<tr>
<td>C1-INH</td>
<td>RhuCIN®, Rucon®, Sanlarus®</td>
<td>Pharming</td>
<td>Recombinant human C1-INH produced in transgenic rabbit</td>
<td>C1-INH replacement</td>
<td>I.V.</td>
<td>Adults: 1 U/kg 1-6 h preprocedure</td>
<td>Rare: risk of anaphylaxis NA</td>
<td>Acute treatment</td>
<td>Acute treatment</td>
<td></td>
</tr>
<tr>
<td>Icatibant acetate</td>
<td>Firazyl®</td>
<td>Shire</td>
<td>Synthetic peptide (10 aa)</td>
<td>Blockage of B2R</td>
<td>Subcutaneous</td>
<td>Adults: 2.4 U 1-6 h procedure</td>
<td>Common: local swelling, pain, pruritus at injection site Theoretical: worsening of an ongoing acute coronary artery disease</td>
<td>Acute treatment, Self-admin</td>
<td>Acute treatment, Self-admin</td>
<td></td>
</tr>
<tr>
<td>Ecallantide</td>
<td>Kalbitor®</td>
<td>Dyax Corp</td>
<td>Recombinant human protein (60 aa)</td>
<td>Selective inhibitor of plasma kallikrein</td>
<td>Subcutaneous</td>
<td>Adults: 1000 IU/kg 1-6 h preprocedure</td>
<td>Uncommon: risk of anaphylaxis Risk of transmission of infectious agent</td>
<td>FDA approved for acute treatment Not approved</td>
<td>FDA approved for LTP Available‡‡</td>
<td>Available‡‡</td>
</tr>
<tr>
<td>Human plasma</td>
<td>Several</td>
<td>Several</td>
<td>Solvent detergent Treated/Fresh Frozen Human plasma</td>
<td>Replacement of deficient protein</td>
<td>I.V.</td>
<td>Adults: 2 U/kg 1-6 h preprocedure†</td>
<td>Risk of hyperkalaemia Worsening of angioedema for substrate supply</td>
<td>Available‡‡ Available‡‡ Available‡‡</td>
<td>Available‡‡ Available‡‡ Available‡‡</td>
<td></td>
</tr>
<tr>
<td>Tranexamic acid</td>
<td>Amicar®, Iplion®</td>
<td>Retspaphm, Xanodyne Pharmaceuticals</td>
<td>Cyclic derivative of epsilon amino capric acid</td>
<td>Antiplasmin—plasminogen activity</td>
<td>Oral, I.V.</td>
<td>Adults: 1-3 g/d, 6 h</td>
<td>Common: nausea, vertigo, diarrhea, postural hypotension, fatigue, muscle cramps with increased muscle enzymes</td>
<td>Available‡‡ Available‡‡ Available‡‡</td>
<td>Available‡‡ Available‡‡ Available‡‡</td>
<td></td>
</tr>
<tr>
<td>Stanozolol</td>
<td>Danabol®, Danocrine®, Daril®</td>
<td>Sanofi-Aventis, Paris, France</td>
<td>Attenuated androgen (17 alpha hydroxylated androgens)</td>
<td>Anabolic action on C1-INH</td>
<td>Oral</td>
<td>2 mg/day or less (divided into 2-3 doses)</td>
<td>Common: weight gain, vilification, acne, altered libido, muscle pain, headaches, depression, fatigue, nausea, constipation, menstrual abnormalities, increase in liver enzymes, hypertension, alterations in lipid profile</td>
<td>Available‡‡ Available‡‡ Available‡‡</td>
<td>Available‡‡ Available‡‡ Available‡‡</td>
<td></td>
</tr>
<tr>
<td>Dantrolene</td>
<td>Danedit®, Dantocine®, Danel®</td>
<td>Saroth-Aventis, Paris, France</td>
<td>Attenuated androgen (17 alpha hydroxylated androgens)</td>
<td>Anabolic action on C1-INH</td>
<td>Oral</td>
<td>200 mg/day or less 5 days per day</td>
<td>Uncommon: decreased growth rate in children, masculinization of female fetus, cholestatic jaundice,</td>
<td>Available‡‡ Available‡‡ Available‡‡</td>
<td>Available‡‡ Available‡‡ Available‡‡</td>
<td>Available‡‡ Available‡‡ Available‡‡</td>
</tr>
</tbody>
</table>
being diagnosed as C1-INH-HAE, all patients should have readily available, a drug of proved efficacy in reverting attacks. Control of the disease should first be attempted administering this drug as soon as the patient realizes that angioedema symptoms start to develop. To have timely intervention, it is highly recommended that patients are trained to home treatment for either subcutaneous or intravenous administration (132). If this approach does not reduce the burden of the disease with significant improvement of the quality of life, continuous prevention treatment should be considered. Antifibrinolytic agents, attenuated androgens, and plasma-derived C1-INH are available for this approach. Although their efficacy had been proved in controlled studies, antifibrinolytics are now rarely used for prophylaxis due a reduced efficacy compared to the other two products (133). Risk/benefit balance of starting long-term prophylaxis and the product to use for this purpose should always be carefully evaluated and individualized to each single patient (10, 116).

A final approach to treat patients with C1-INH-HAE is to prevent attacks on a short term. This approach is mainly addressed to avoid angioedema complications of medical maneuvers, namely oral procedures that may trigger upper airways edema. Specific indications present in therapeutic consensus documents are derived from expert opinion and uncontrolled series of patients (134–136). Plasma-derived C1-INH, given at doses effective for on demand and as close as possible to the procedure, appears as the most rational approach because it is promptly effective and has a sufficient half-life (116, 137, 138).

Hereditary angioedema with normal C1 inhibitor and factor XII mutation (FXII-HAE) and of unknown origin (U-HAE)

In 1985, a large family in which five women suffered from recurrent angioedema of the skin associated with relapsing episodes of abdominal pain attacks and episodes of upper airway obstruction was observed (9). Surprisingly, all of the women had normal C1-INH function. In 2000, this family and nine additional families with similar symptoms and a normal C1-INH function were identified (9). Interestingly, in these 10 families, a total of 36 women, but not a single man, were affected. In this initial description, the terms ‘hereditary angioedema with normal C1-INH’ or ‘hereditary angioedema type III’ were proposed. Through 2003, all the patients described in the literature were women, and therefore, it was assumed that the clinical phenotype might be limited to the female sex (139–141). However, in 2006, a family with dominantly inherited angioedema and normal C1-INH was described in which not only five female but also three male family members were clinically affected (142).

Factor XII genetic defect

In May 2006, genetic mutations in six index patients of 20 families and in 22 patients of the corresponding six families were identified: two different missense mutations have been
verified which were assumed to be the cause of the disease according to the co-segregation pattern of mutations and the clinical symptoms in women (143). The location of these mutations was the same locus, 5q33-qter as the Hageman factor, or coagulation F12 gene (Online Mendelian Inheritance in Man # 610619). One mutation leads to a threonine-to-lysine substitution (Thr328Lys) and the other to a threonine-to-arginine substitution (Thr328Arg). Both of these mutations were located on the exon 9. It was also found that the index patients of 14 further families with HAE and normal C1-INH did not show these mutations (143). More recently, a large deletion of 72 base pairs (c.971_1018+24del72) and a duplication of 18 base pairs (c.892_909dup) both located in the same region of F12 have been described (144, 145). At present, we have patients with HAE with normal C1-INH and mutation in the F12 gene and patients with normal C1-INH and unknown genetic defect (146–150). Hence, for patients with family history of angioedema and normal C1-INH, we propose to use the term factor XII-HAE (FXII-HAE) when mutation in F12 gene can be detected and unknown HAE (U-HAE) when no genetic defect can be identified. FXII-HAE should be used also for patients carrying mutations in the coagulation F12 gene even when family history of angioedema is not present, as family studies showed that angioedema symptoms segregate with the mutations (143). It is further recommended that the term HAE type III no longer be used, because HAE type I and II identify two specific types of C1-INH deficiency.

Clinical presentation

Because many case lists of HAE and normal C1-INH were presented as HAE type III before FXII-HAE subgroup was identified, separating the characteristics of U-HAE from FXII-HAE is difficult. Sex prevalence in U-HAE is not clearly reported, while almost just women are affected with FXII-HAE. F12 gene mutations are transmitted as an autosomal dominant trait with low penetrance; asymptomatic carriers are >90% in male gender and around 40% in female (146, 149, 150). The clinical symptoms include recurrent skin swellings, abdominal pain attacks, tongue swelling, and upper airways edema. No difference in clinical symptoms due to the presence of F12 gene mutations has been identified (146, 147, 151). Urticaria does not occur at any time in any of these patients. The skin swellings typically last 2–5 days; they affect mainly the extremities and the face. The abdominal attacks likewise last 2–5 days and are manifested as severe crampy pain. In a comprehensive study, 138 patients with U-HAE/FXII-HAE from 43 unrelated families were examined (146). A majority of patients had symptoms of skin swelling (92.8%), tongue swelling (53.6%), and abdominal attacks (50%). Laryngeal edema (25.4%) and uvular edema (21.7%) also were frequent, whereas edema episodes of other organs were rare (3.6%). In many women, the clinical symptoms were provoked by oral contraceptives, hormonal replacement therapy, or pregnancy.

Diagnosis

Diagnosis of U-HAE is purely based on clinical findings and requires that patients have the (i) above-mentioned clinical symptoms, (ii) one or more family members also affected with these symptoms, (iii) the exclusion of familial and hereditary chronic urticaria with urticaria-associated angioedema, (iv) normal C1-INH activity and protein in plasma, and (v) no HAE-associated mutation in F12 gene. FXII-HAE has analogous clinical criteria, but with the presence of an HAE-associated mutation in F12 gene, which may also identify solitary cases.

The laboratory diagnosis of FXII-HAE is purely genetic, while there are no confirmatory laboratory tests for U-HAE. The existence of sporadic cases of U-HAE can be assumed, but not confirmed for the moment as such a diagnosis is solely based on family history of angioedema.

Therapeutic approach

Patients with U-HAE/FXII-HAE do not respond to corticosteroids and antihistamines (152). Based on the presumed pathophysiology, several potential treatment options are available for U-HAE/FXII-HAE, including C1-INH agents, icatibant, ecallantide, progesterone, danazol, and tranexamic acid. However, there are no published controlled studies using any of these novel therapies in these patients.

Final Consensus

Angioedema identifies recurrent edema caused by the release of one of several existing vasoactive mediators. When angioedema arises together with wheals, these patients with recurrent angioedema and wheals should be diagnosed as having urticaria.

Statement 1: Angioedema is diagnosed when a patient presents with recurrent angioedema symptoms in the absence of wheals

Angioedema can be differentiated based on specific characteristics. The discussion among experts suggested first distinguishing hereditary from nonhereditary forms. Angioedema should be considered hereditary in the presence of a specific risk factor for transmission to offspring. Identified risk factors supporting a diagnosis of HAE are as follows.

Statement 2: Angioedema is defined as hereditary when (i) there is family history of angioedema within a second-degree relative; (ii) there is a mutation in the SERPING1 or the F12 gene that has been demonstrated to be associated with angioedema; and (iii) there is a familial deficiency of C1-INH. All other forms of angioedema should be considered as acquired

Based on the present knowledge, experts distinguished seven specific forms of angioedema within the two categories of
Acquired and hereditary. Characteristics for diagnosis are reported in Table 2.

**Statement 3: Angioedema should be diagnosed as follows:**

1. Acquired
   1.1 Idiopathic histaminergic acquired angioedema (IH-AAE)
   1.2 Idiopathic nonhistaminergic acquired angioedema (InH-AAE)
   1.3 Acquired angioedema related to angiotensin-converting enzyme inhibitor (ACEI-AAE)

2. Hereditary
   2.1 Hereditary angioedema with C1-INH deficiency (C1-INH-HAE)
   2.2 Hereditary angioedema with FXII mutation (FXII-HAE)
   2.3 Hereditary angioedema of unknown origin (U-HAE)

Drugs approved to treat angioedema are limited to C1-INH-HAE; their use in the other forms is off label. Specific indications are reported in Table 3.

---

### Table 2 Characteristics of different forms of angioedema

<table>
<thead>
<tr>
<th></th>
<th>Acquired</th>
<th>Hereditary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IH-AAE</td>
<td>InH-AAE</td>
</tr>
<tr>
<td>Peripheral AE</td>
<td></td>
<td>++ (11, 17)</td>
</tr>
<tr>
<td>Facial AE</td>
<td>+++</td>
<td>++ (11, 17)</td>
</tr>
<tr>
<td>Abdominal AE</td>
<td>–</td>
<td>+ (11, 17)</td>
</tr>
<tr>
<td>Upper respiratory AE</td>
<td>+</td>
<td>++ (11, 17)</td>
</tr>
<tr>
<td>Age at onset</td>
<td>Any</td>
<td>Any</td>
</tr>
<tr>
<td>Speed of onset</td>
<td>&lt;6</td>
<td>12</td>
</tr>
<tr>
<td>Duration</td>
<td>&lt;24 h</td>
<td>24–48</td>
</tr>
<tr>
<td>Male/Female</td>
<td>1 : 1</td>
<td>1 : 1</td>
</tr>
<tr>
<td>Ethnic predilection</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Diagnostic characteristic</td>
<td>Unidentified etiology, prevented by antihistamine</td>
<td>Unidentified etiology, Nonprevented by antihistamine</td>
</tr>
</tbody>
</table>

Based on experts’ opinion and reference reported in brackets.

### Table 3 Evidence for treatment efficacy in different forms of angioedema

<table>
<thead>
<tr>
<th></th>
<th>Acquired</th>
<th>Hereditary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IH-AAE</td>
<td>InH-AAE</td>
</tr>
<tr>
<td>Antihistamine prophylaxis</td>
<td>Prevention</td>
<td>None</td>
</tr>
<tr>
<td>C1 inhibitor acute</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>C1 inhibitor prophylaxis</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Icatibant acute</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ecallantide acute</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Att. Androgen prophylaxis</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Antifibrinolytic prophylaxis</td>
<td>None</td>
<td>Case list (11, 17)</td>
</tr>
</tbody>
</table>

Based on experts’ opinion and references reported in brackets.
Statement 4: licensed therapy of angioedema is limited to C1-INH-HAE. Other forms can just be treated off label based on small noncontrolled studies and expert experience.

In conclusion, the present knowledge allows recognizing angioedema as a separate nosology entity, which is comprised of different forms that can be diagnosed based on specific criteria. The absence of studies on angioedema, other than C1-INH-HAE, prevents designing an evidence-based therapeutic strategy: development of controlled studies to properly treat angioedema-related mortality and disability should be an objective for the future.

Author contributions

All authors and listed members of HAWK, contributed to the discussion of the topics of the manuscript during the meeting, provided critical reading and final approval. The authors contributed to define the general structure and repeatedly reviewed the manuscript throughout its drafting. Inherent literature and first draft of each part were provided as follows: MC introduction; WA & APK IH-AAE; AG & MT IhH-AAE; HF & MB ACEI-AAE; JAB & AZ C1-INH-AAE; TC & MAR C1-INH-HAE; AB & KB FXII/Unknown HAE; BZ & MC final consensus; TC Table 1; MC Tables 2 and 3; AG figure. MC work coordination.

Conflicts of interest

MC: Consultant for CSL Behring, Viropharma, Dyax, SOBI, Pharming, BioCryst, Sigma Tau; Research/educational grant from Shire, CSL Behring. WA: Advisor and speaker for CSL Behring, Shire, and ViroPharma; funding to attend conferences and other educational events from CSL Behring, Pharming, Shire, and ViroPharma; donations to his departmental fund and participated in clinical trials for Shire. AB: Clinical Research funding from Dyax, Shire, CSL, Viropharma, Santarus; Advisory Board: Dyax, Santarus, Shire. MB: Consultant for Shire. JAB: Principal Investigator, Consultant, and Speaker for: Viropharma, CSL Behring, Dyax, and Shire; Principal Investigator and Consultant for: Pharming; Editorial Board: Journal of Angioedema; Medical Advisory Board: HA EA organization. KB: Consultant for CSL Behring, Shire, and Viropharma. TC: Speaker fees from Shire HG T, Inc./Jerini AG, and ViroPharma; Consultancy fees from Shire HG T, Inc./Jerini AG, ViroPharma, and CSL Behring; Funding for travel and meeting attendance from CSL Behring and Shire HG T, Inc.; Has participated in clinical trials for Dyax, Pharming, CSL Behring, and Shire HG T, Inc./Jerini AG. AG: has served on Advisory Boards and as speaker for Shire. HF: Speaker Shire and Swedish Orphan Biovitrum; Consultant for CSL Behring, Pharming, Shire, Swedish Orphan Biovitrium, and Viropharma; Travel expenses from CSL Behring, Pharming, Shire, Swedish Orphan Biovitrium, and Viropharma. APK: Grant support from Dyax, Shire, CSL Behring, Viro Pharma; Consultant for Dyax, Genentech, BioCryst; Lecture Series: Robert Michael Educational Institute, Dyax. MAR: Research funding: CSL Behring, Dyax, Pharming, Shire, ViroPharma; Consultant: BioCryst, CSL Behring, Dyax, Isis, Santarus, Shire, ViroPharma; Speaker: CSL Behring, Dyax, Shire, ViroPharma. MT: research grant from CSL Behring, consultant for Shire, Viropharma, and SOBI. BZ: Research funding: Shire; Consultant: CSL Behring, Dyax, Isis, BioCryst; Speaker: Dyax, RMEI.

References


HWA K angioedema classification

64. Hauptmann G, Lang JM, North ML.


94. Stray-Pedersen A, Abrahamsen TG, Frøiland SS. Primary immunodeficiency


Appendix

HAWK (Hereditary Angioedema International Working Group):

Emel Aygören-Pürsün, Germany; María-Luisa Baeza, Spain; Noemi-Anna Bara, Romania; Alicia Lara Becerra, Mexico; Karen Binkley, Canada; Janne Bjorkander, Sweden; Isabelle Boccon-Gibod, France; Paolo Borrelli, Italy; Laurence Bouillet, France; Maria Bova Italy; Tom Bowen, Canada; Manuel Branco-Ferreira, Portugal; Anette Bygum, Denmark; Mauro Cancian, Italy; Maria Graça Castel-Branco, Portugal; Sven Cichon, Swiss; Enrico Cilliari Italy; Stefan Cimbollek, Spain; Timothy J. Craig, US; Alvin Davis, US; Isabella Del Corso, Italy; Christian Drouet, France; José Fabiani, Argentina; Michael Frank, US; Mark Gompels, UK; Teresa Gonzalez-Quevedo, Spain; Richard Gower, US; Clive Grattan, UK; Adriane Groftik, Germany; Mar Guilarte, Spain; Erik Hack, The Netherlands; Maria E. Hernandez Landeros, Mexico; Iris Leibovich, Israel; Henri Li, US; Bob Lock, UK; Hilary Longhurst, UK; William R Lumry, US; Markus Magerl, Germany; Alex Malbran, Argentina; Ludovic Martin, France; Inmaculada Martinez-Saguer, Germany; Juan J. Matta Campos, Mexico; Marcus Maurer, Germany; Eniko Mihaly, Romania; Paola Minale, Italy; Dumitru Moldovan, Romania; Vincenzo Montinaro, Italy; Sergio Neri, Italy; Sandra Nieto, Mexico; Patrick Nordenfelt, Sweden; Krystyna Obtulowicz, Poland; Celso Pereira, Portugal; Roberto Pericone, Italy; Nieves Prior, Spain; Paolina Quattrrocchi, Italy; Thomas Renné, Sweden; Avner Reshfer, Israel; Oliviero Rossi, Italy; Anna Sala-Cunill, Spain; Peter Spaeth, Swiss; Petra Staubach-Renz, Germany; Marcin Stobiecki Poland; Lilian Varga, Hungary; Walter Wullemain, Swiss; Giuseppina Zanierato, Italy; Alessandra Zoli, Italy.

© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd